Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Dabigatran Etexilate 150 mg hard capsule

Active Ingredient:
dabigatran etexilate
Company:  
Glenmark Pharmaceuticals Europe Ltd See contact details
ATC code: 
B01AE07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Dabigatran Etexilate Paediatric - Guide

This guide provides recommendations for the use of dabigatran etexilate in the paediatric population in order to minimise the risk of bleeding

{pdf_link}

Dabigatran Etexilate Stroke - Guide

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

{pdf_link}

Dabigatran Etexilate Hip, Knee - Guide

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Glenmark Pharmaceuticals Europe Ltd
Company image
Address
Building 2, Croxley Park, Watford, WD18 8YA
Telephone
+44 (0)1923 202 950
Fax
+44 (0)1923 251137
Medical Information Direct Line
0800 458 0383
E-mail
[email protected]
Stock Availability
+44 (0)1923 202 950
WWW
www.glenmarkpharma.com